Company news

Amneal Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Amneal Reports First Quarter 2025 Financial Results

May 1, 2025

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month

April 10, 2025

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

April 6, 2025

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

April 2, 2025

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

March 31, 2025

Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

March 2, 2025

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

February 27, 2025

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

February 18, 2025

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

January 22, 2025

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

November 20, 2024

Amneal Reports Third Quarter 2024 Financial Results

November 7, 2024

Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets

October 20, 2024

Amneal to Report Third Quarter 2024 Results on November 8, 2024

October 7, 2024

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

September 30, 2024

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease

September 22, 2024

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

September 4, 2024

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

August 19, 2024

Amneal Reports Second Quarter 2024 Financial Results

August 8, 2024

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

August 6, 2024

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

July 28, 2024

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

July 8, 2024

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

June 30, 2024

Amneal Releases 2023 Environmental, Social and Governance Report

June 27, 2024

Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies

June 4, 2024

Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California

May 21, 2024

Amneal Reports First Quarter 2024 Financial Results

May 2, 2024

Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

April 23, 2024

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

April 15, 2024

Amneal to Report First Quarter 2024 Results on May 3, 2024

April 9, 2024

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

March 24, 2024

Amneal Reports Fourth Quarter and Full Year 2023 Financial Results

February 29, 2024

Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

February 26, 2024

Amneal Announces Complete Response Resubmission for IPX203 New Drug Application

February 7, 2024

Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024

January 30, 2024

Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension

January 9, 2024

Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023

January 3, 2024

Amneal Announces Move to Nasdaq

December 14, 2023

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

December 6, 2023

Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules

November 30, 2023

Amneal Reports Third Quarter 2023 Financial Results

November 6, 2023

Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance

October 22, 2023

Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio

October 11, 2023

Amneal to Report Third Quarter 2023 Results on November 7, 2023

October 4, 2023

Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate

September 5, 2023

Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection

September 5, 2023

Amneal Receives First Product Approval in China

September 5, 2023

Amneal Reports Second Quarter 2023 Financial Results

August 3, 2023

Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

July 25, 2023

Amneal to Report Second Quarter 2023 Results on August 4, 2023

July 5, 2023

Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

July 2, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 56 decks. Every deck is listed under its year.